IL158347A0 - Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis - Google Patents
Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresisInfo
- Publication number
- IL158347A0 IL158347A0 IL15834702A IL15834702A IL158347A0 IL 158347 A0 IL158347 A0 IL 158347A0 IL 15834702 A IL15834702 A IL 15834702A IL 15834702 A IL15834702 A IL 15834702A IL 158347 A0 IL158347 A0 IL 158347A0
- Authority
- IL
- Israel
- Prior art keywords
- iontophoresis
- gene therapy
- chimeric oligonucleotides
- oligonucleotides delivered
- delivered
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/836,439 US20030045830A1 (en) | 2001-04-17 | 2001-04-17 | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| PCT/IB2002/002310 WO2002083184A2 (en) | 2001-04-17 | 2002-04-17 | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158347A0 true IL158347A0 (en) | 2004-05-12 |
Family
ID=25271967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15834702A IL158347A0 (en) | 2001-04-17 | 2002-04-17 | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20030045830A1 (de) |
| EP (1) | EP1379665A2 (de) |
| JP (1) | JP2004532844A (de) |
| KR (1) | KR20040018356A (de) |
| AU (1) | AU2002311523A1 (de) |
| BR (1) | BR0208962A (de) |
| CA (1) | CA2443923A1 (de) |
| IL (1) | IL158347A0 (de) |
| MX (1) | MXPA03009528A (de) |
| WO (1) | WO2002083184A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045830A1 (en) * | 2001-04-17 | 2003-03-06 | De Bizemont Therese | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050222061A1 (en) | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| US20070218551A1 (en) * | 2003-10-02 | 2007-09-20 | Chuan-Yuan Li | Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy |
| US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
| US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| US7729761B2 (en) * | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
| US20070299420A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Delivery of an agent using iontophoresis |
| US20070299386A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Delivery of an ocular agent using iontophoresis |
| WO2008125908A2 (en) * | 2006-12-05 | 2008-10-23 | Eyegate Pharma S.A. | Enhanced retinal delivery of a nucleic acid through iontophoresis |
| JP5832293B2 (ja) | 2008-12-04 | 2015-12-16 | オプコ ファーマシューティカルズ、エルエルシー | 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法 |
| US8207138B2 (en) * | 2009-05-19 | 2012-06-26 | Medtronic, Inc. | Methods and devices for improved efficiency of RNA delivery to cells |
| ES2567321T3 (es) * | 2011-08-16 | 2016-04-21 | Institut National de la Santé et de la Recherche Médicale | Dispositivo para el tratamiento de una enfermedad ocular |
| EP2559443A1 (de) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und pharmazeutische Zusammensetzungen zur Behandlung einer Augenerkrankung bei einem Patienten |
| CN107532162A (zh) * | 2014-12-12 | 2018-01-02 | 托德·M·伍尔夫 | 用于利用寡核苷酸编辑细胞中核酸的组合物和方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141359A (en) * | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
| US4301794A (en) * | 1978-10-18 | 1981-11-24 | Robert Tapper | Method for iontophoretic treatment |
| US4250878A (en) * | 1978-11-22 | 1981-02-17 | Motion Control, Inc. | Non-invasive chemical species delivery apparatus and method |
| US4747819A (en) * | 1984-10-29 | 1988-05-31 | Medtronic, Inc. | Iontophoretic drug delivery |
| US4752285B1 (en) * | 1986-03-19 | 1995-08-22 | Univ Utah Res Found | Methods and apparatus for iontophoresis application of medicaments |
| US4915685A (en) * | 1986-03-19 | 1990-04-10 | Petelenz Tomasz J | Methods and apparatus for iontophoresis application of medicaments at a controlled ph through ion exchange |
| US5250022A (en) * | 1990-09-25 | 1993-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose |
| US4979938A (en) * | 1989-05-11 | 1990-12-25 | Iomed, Inc. | Method of iontophoretically treating acne, furuncles and like skin disorders |
| US6139537A (en) * | 1990-11-01 | 2000-10-31 | Tapper; Robert | Iontophoretic treatment system |
| MX9206990A (es) * | 1991-12-03 | 1993-06-01 | Alza Corp | Dispositivo iontoforetico de surtido y suministro de energia para el mismo. |
| DK0733059T3 (da) * | 1993-12-09 | 2000-10-16 | Univ Jefferson | Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler |
| JPH09511671A (ja) * | 1994-08-22 | 1997-11-25 | イオメド インコーポレイテッド | 水和水段を組み込んだイオントフォレティック（ｉｏｎｔｏｐｈｏｒｅｔｉｃ）デリバリー装置 |
| US5498235A (en) * | 1994-09-30 | 1996-03-12 | Becton Dickinson And Company | Iontophoresis assembly including patch/controller attachment |
| AUPM982694A0 (en) * | 1994-12-02 | 1995-01-05 | University Of Queensland, The | Iontophoresis method and apparatus |
| JPH09103494A (ja) * | 1995-06-09 | 1997-04-22 | Takeda Chem Ind Ltd | イオントフォレシス用薬物溶解液 |
| FR2747313B1 (fr) * | 1996-04-16 | 1998-06-05 | Lhd Lab Hygiene Dietetique | Dispositif d'administration transdermique de medicaments par ionophorese |
| US5760012A (en) * | 1996-05-01 | 1998-06-02 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
| US6018679A (en) * | 1997-01-29 | 2000-01-25 | Novartis Finance Corp. | Iontophoretic transdermal delivery and control of adverse side-effects |
| FR2773320B1 (fr) * | 1998-01-05 | 2000-03-03 | Optisinvest | Dispositif pour le transfert intraoculaire de produits actifs par iontophorese |
| US6148231A (en) * | 1998-09-15 | 2000-11-14 | Biophoretic Therapeutic Systems, Llc | Iontophoretic drug delivery electrodes and method |
| SE9803891D0 (sv) * | 1998-11-13 | 1998-11-13 | Pharmacia & Upjohn Ab | Protein Variants |
| JP2002542805A (ja) * | 1999-04-30 | 2002-12-17 | ユニバーシティ オブ フロリダ | アデノ随伴ウイルス送達リボザイム組成物および使用方法 |
| EP1178836A2 (de) * | 1999-05-21 | 2002-02-13 | The Board of Trustees of The Leland S. Stanford Junior University | Verwendung von chimaere mutationsvektoren zur änderung endogener sequenzen in festem gewebe |
| US20030045830A1 (en) * | 2001-04-17 | 2003-03-06 | De Bizemont Therese | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
-
2001
- 2001-04-17 US US09/836,439 patent/US20030045830A1/en not_active Abandoned
-
2002
- 2002-04-17 KR KR10-2003-7013665A patent/KR20040018356A/ko not_active Ceased
- 2002-04-17 IL IL15834702A patent/IL158347A0/xx unknown
- 2002-04-17 JP JP2002580985A patent/JP2004532844A/ja active Pending
- 2002-04-17 MX MXPA03009528A patent/MXPA03009528A/es not_active Application Discontinuation
- 2002-04-17 CA CA002443923A patent/CA2443923A1/en not_active Abandoned
- 2002-04-17 BR BR0208962-9A patent/BR0208962A/pt not_active IP Right Cessation
- 2002-04-17 AU AU2002311523A patent/AU2002311523A1/en not_active Abandoned
- 2002-04-17 WO PCT/IB2002/002310 patent/WO2002083184A2/en not_active Ceased
- 2002-04-17 EP EP02738443A patent/EP1379665A2/de not_active Withdrawn
-
2004
- 2004-10-18 US US10/965,905 patent/US20060031946A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002083184A2 (en) | 2002-10-24 |
| US20060031946A1 (en) | 2006-02-09 |
| KR20040018356A (ko) | 2004-03-03 |
| BR0208962A (pt) | 2004-07-27 |
| AU2002311523A1 (en) | 2002-10-28 |
| EP1379665A2 (de) | 2004-01-14 |
| US20030045830A1 (en) | 2003-03-06 |
| CA2443923A1 (en) | 2002-10-24 |
| WO2002083184A3 (en) | 2003-09-18 |
| MXPA03009528A (es) | 2004-12-06 |
| JP2004532844A (ja) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002311523A1 (en) | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis | |
| AU2003213771A8 (en) | Method for modification of radiotherapy treatment delivery | |
| ZA200408111B (en) | Treatment of gastroparesis. | |
| AU2003297474A8 (en) | Methods of inhibiting gene expression by rna interference | |
| HUP0402656A3 (en) | A cell therapy method for the treatment of tumors | |
| EP1638931A4 (de) | Verfahren zum zielgerichteten einsatz eines therapeutischen mittels | |
| PL345207A1 (en) | Gene therapy method | |
| EP1455825A4 (de) | Behandlung von b-zell-vermittelten krankheiten durch modulation der dr6-aktivität | |
| GB0013108D0 (en) | Extended duration of airway gene therapy | |
| GB0218803D0 (en) | Targeted gene modification by single-standed DNA oligonucleotides | |
| AU2002345658A1 (en) | Methods for targeted expression of therapeutic nucleic acid | |
| GB0228751D0 (en) | Method of design using genetic programming | |
| AU2003285079A1 (en) | Neurostimulation therapy manipulation | |
| GB9924981D0 (en) | Gene therapy | |
| GB9900009D0 (en) | Gene therapy | |
| IL163553A0 (en) | Microorganism for genetic therapeutic treatment ofproliferative diseases | |
| EP1435389A4 (de) | Verfahren zur bewertung der wirksamkeit einer nukleinsäuretherapie | |
| GB0104555D0 (en) | New Therapeutic method | |
| AU2003245575A1 (en) | Oligonucleotide directed misfolding of rna | |
| GB0216776D0 (en) | Control of gene expression | |
| GB0406539D0 (en) | Gene therapy | |
| AU2002322013A1 (en) | Therapeutic dna vaccination | |
| EP1370138A4 (de) | Gentherapie für nervengewebe | |
| AU2003260820A1 (en) | Nephritis treatment by gene therapy | |
| IL144531A0 (en) | A method of seed priming |